Last mentioned: Mar 22, 2026
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Candel Public Offering
Candel Therapeutics prices $100M public offering at $5.45 per share.
Trial Data Release
Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
GDP Release
U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
Grail Earnings
Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.
This page surfaces every story mentioning Grail across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Grail was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |